4-HO-MPT

4-HO-MPT exhibits exceptionally potent 5-HT2B receptor affinity (Ki = 8 nM), approximately 14-fold greater than at 5-HT2A (Glatfelter et al. 2023). Chronic 5-HT2B agonism is the established mechanism underlying cardiac valvulopathy caused by fenfluramine and ergot derivatives. While valvular damage in those contexts required chronic daily exposure, no data exist to characterize cardiac safety of 4-HO-MPT at any frequency. Individuals with pre-existing valvular pathology face elevated theoretical risk.

Lithium combined with serotonergic psychedelics is associated with increased seizure risk in case literature. The mechanism is incompletely characterized. This is a class-level contraindication applied to all 5-HT2A agonist psychedelics including 4-HO-MPT.

Serotonergic psychedelics acting via 5-HT2A agonism carry a class-level risk of precipitating acute psychotic episodes in individuals with personal or family history of schizophrenia, schizoaffective disorder, or other psychotic spectrum conditions. No 4-HO-MPT-specific case reports exist, but the mechanism is well-established for the class.

No reproductive or developmental toxicity data exist for 4-HO-MPT. The potent 5-HT2B affinity (Ki = 8 nM) is of theoretical concern because 5-HT2B receptors are expressed during cardiac development. This is a precautionary absolute contraindication in the absence of safety data.

Monoamine oxidase A is expected to be a primary degradation pathway for 4-HO-MPT. Co-administration with MAOIs (pharmaceutical or botanical, e.g., harmine/harmaline from Peganum harmala) would dramatically amplify and prolong effects while creating serotonin syndrome risk. This applies to both irreversible (phenelzine, tranylcypromine) and reversible (moclobemide) MAO-A inhibitors.

SSRIs and SNRIs create serotonin syndrome risk through mechanism overlap — elevated synaptic serotonin combined with potent post-synaptic 5-HT2A/2B/1A agonism by 4-HO-MPT. Chronic SSRI use may also attenuate subjective psychedelic effects through 5-HT2A receptor downregulation. Classified as relative rather than absolute because risk is dose-dependent and clinical outcomes vary.

Tramadol inhibits serotonin reuptake (SERT) and combined with 4-HO-MPT's potent post-synaptic serotonin receptor agonism creates additive serotonergic load sufficient to precipitate serotonin syndrome. This interaction is classified as dangerous in the substance's interaction database. The mechanism is pharmacologically well-established though no specific case involving 4-HO-MPT has been published.